Search alternatives:
gap decrease » a decrease (Expand Search), gain decreased (Expand Search), mean decrease (Expand Search)
Showing 1 - 20 results of 2,005 for search '(( significant burden decrease ) OR ( significant gap decrease ))', query time: 0.44s Refine Results
  1. 1
    Health inequalities in the burden of IBD among WCBA.

    Health inequalities in the burden of IBD among WCBA. by Jiefeng Zhao (9090305)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 2
    Frontier analysis for the potential for improvement in reducing the burden of IBD among WCBA across 204 countries and regions.

    Frontier analysis for the potential for improvement in reducing the burden of IBD among WCBA across 204 countries and regions. by Jiefeng Zhao (9090305)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Decomposition analysis of the changes in prevalence (A), DALYs (B), and mortality (C) rates of IBD among women across global, 5 SDI and 21 GBD regions.

    Decomposition analysis of the changes in prevalence (A), DALYs (B), and mortality (C) rates of IBD among women across global, 5 SDI and 21 GBD regions. by Jiefeng Zhao (9090305)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Estimated prevalence (A), DALYs (B), and mortality (C) rates for IBD among WCBA by 2040.

    Estimated prevalence (A), DALYs (B), and mortality (C) rates for IBD among WCBA by 2040. by Jiefeng Zhao (9090305)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    The global changes of AS prevalence, DALYs, and mortality rates of IBD among women from 1990 to 2021.

    The global changes of AS prevalence, DALYs, and mortality rates of IBD among women from 1990 to 2021. by Jiefeng Zhao (9090305)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Estimated prevalence (A), DALYs (B), and mortality (C) rates of IBD in different age subgroups of WCBA by 2040.

    Estimated prevalence (A), DALYs (B), and mortality (C) rates of IBD in different age subgroups of WCBA by 2040. by Jiefeng Zhao (9090305)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    The global changes of prevalence (A-C), DALYs (D-F), and mortality (G-I) rates of IBD among WCBA from 1990 to 2021.

    The global changes of prevalence (A-C), DALYs (D-F), and mortality (G-I) rates of IBD among WCBA from 1990 to 2021. by Jiefeng Zhao (9090305)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  9. 9
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  10. 10
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  11. 11
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  12. 12
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  13. 13
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  14. 14
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  15. 15
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  16. 16
    Significantly Enriched Pathways.

    Significantly Enriched Pathways. by Jiyong Zhang (2498740)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Trends in the burden of stroke attributed to smoking.

    Trends in the burden of stroke attributed to smoking. by Jaber S. Alqahtani (8822396)

    Published 2025
    Save to List
    Saved in:
  18. 18
    Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments.

    Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. by Cathryn S. D. Maienza (20629929)

    Published 2025
    Save to List
    Saved in:
  19. 19
    Modified version of the Caregiving Stress Model for Post Intensive Care Syndrome – Family impairments.

    Modified version of the Caregiving Stress Model for Post Intensive Care Syndrome – Family impairments. by Cristobal Padilla-Fortunatti (21376807)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    SPIRIT schedule: Timeline of recruitment and assessment. <i>t</i><sub>0</sub>: Daily screening; <i>t</i><sub>1</sub>: Between the 3<sup>rd</sup> and 10<sup>th</sup> day of ICU admission; t<sub>2</sub>: Near after ICU discharge; <i>t</i><sub>3</sub>: 3 months after hospital discharge; <i>t</i><sub>4</sub>: 6 months after hospital discharge.

    SPIRIT schedule: Timeline of recruitment and assessment. <i>t</i><sub>0</sub>: Daily screening; <i>t</i><sub>1</sub>: Between the 3<sup>rd</sup> and 10<sup>th</sup> day of ICU admi... by Cristobal Padilla-Fortunatti (21376807)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: